FMBA announces breakthrough candidate ‘Enteromix’; first focus on colorectal cancer
Moscow/Vladivostok: Russian scientists have developed a new cancer vaccine that is ready for clinical use, according to the country’s Federal Medical and Biological Agency (FMBA). The announcement was made by FMBA head Veronika Skvortsova at the 10th Eastern Economic Forum in Vladivostok, Russian news agency TASS reported.
Enteromix: An mRNA breakthrough
The vaccine, called Enteromix, uses mRNA technology, the same method applied in some Covid-19 vaccines. Instead of relying on weakened viruses, mRNA vaccines instruct the body’s cells to produce proteins that activate the immune system against cancer cells.
Skvortsova said that years of research, including three years of mandatory preclinical trials, have been completed. Results showed the vaccine was safe, even after repeated doses, and demonstrated remarkable efficacy.
“In some cases, tumors shrank or slowed in growth by 60% to 80%, depending on the type of cancer. Survival rates among test subjects also improved significantly,” she said.
Target cancers: colorectal, brain, and melanoma
The first stage of clinical application will target colorectal cancer, which affects the large intestine. Parallel research is progressing on vaccines for:
- Glioblastoma – an aggressive brain cancer
- Melanoma – including ocular melanoma, a rare form that affects the eye
Global stage debut
The announcement was made at the Eastern Economic Forum, which drew over 8,400 participants from 75 countries. The development adds momentum to global efforts in harnessing mRNA technology for cancer treatment, with Russia joining a competitive field of international oncology research.